Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Long-term open-label extension trial for subjects completing the phase 3 trial of fesoterodine (SP584) for the treatment of overactive bladder syndrome.

Next Previous
Search
Trial Profile

Long-term open-label extension trial for subjects completing the phase 3 trial of fesoterodine (SP584) for the treatment of overactive bladder syndrome.

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 30 Oct 2014

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Fesoterodine (Primary)
  • Indications Overactive bladder
  • Focus Adverse reactions
  • Sponsors Pfizer; UCB

Most Recent Events

  • 09 Apr 2008 Pfizer has replaced UCB Pharma as a trial sponsor, according to ClinicalTrials.gov.
  • 18 Sep 2006 New trial record.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top